Home > Haematology > ASH 2019 > Late-Breaking Abstracts > Anti-CD70 is safe with hypomethylating agents in AML

Anti-CD70 is safe with hypomethylating agents in AML

Presented By
Prof. Adrian Ochsenbein, Bern University Hospital, Switzerland
ASH 2019
Prof. Adrian Ochsenbein (Bern University Hospital, Switzerland) presented the results of the open-label, non-randomised combined phase 1 and 2 study looking at newly diagnosed acute myeloid leukaemia (AML) treatment with hypomethylating agent azacitidine. These results showed that better clinical benefit could be achieved by the addition of the anti-CD70 monoclonal antibody cusatuzumab. Cusatuzumab in combination with azacitidine appeared safe and tolerable [1]. Leukaemia stem cells are known to express the surface markers CD70 and CD27, and there is substantial pre-clinical data to suggest that cusatuzumab blocks CD70–CD27 signalling. The authors hypothesised that combining cusatuzumab with azacitidine would eradicate leukaemia stem cells. This study provided the first-in-human data of this combination. The study enrolled 12 patients with newly diagnosed AML, who received 1 infusion with cusatuzumab, ranging from 1-20 mg/kg, followed after 14 days ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on